SYK
Stryker Corporation · Healthcare · Medical - Devices
Momentum-inputs (vergelijkbare managers): breedte van houders 0.0% · aandelenstroom -1.1% · netto nieuwe posities 0.0% · formule
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q2 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 438.61K | $109.42M | n/a | −3 |
| Q2 2026 | 170 | +2 | 220.81M | $69.86B | +7 | −6 |
| Q1 2026 | 172 | -2 | 215.42M | $70.87B | +1 | −4 |
| Q4 2025 | 173 | -1 | 229.53M | $80.67B | +1 | −1 |
| Q3 2025 | 25 | +3 | 142.80M | $52.79B | +4 | −2 |
| Q2 2025 | 20 | 0 | 117.11M | $46.33B | +1 | −1 |
| Q1 2025 | 17 | -2 | 51.08M | $19.01B | n/a | −2 |
| Q4 2024 | 19 | 0 | 52.07M | $18.75B | +1 | −1 |
| Q3 2024 | 18 | +2 | 39.19M | $14.15B | +2 | n/a |
| Q2 2024 | 16 | n/a | 41.27M | $14.03B | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passief) | 33.50M | n/a | $13.25B | 0.2% | n/c | 1 | SEC ↗ ×6 |
| 2 | BlackRock ✦ (passief) | 26.63M | n/a | $10.53B | 0.2% | n/c | 1 | SEC ↗ ×21 |
| 3 | State Street Global Advisors ✦ (passief) | 14.96M | +1.0% | $5.93B | 0.2% | ▲ Add | 3 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 11.90M | -1.9% | $4.71B | 0.5% | ▼ Trim | 5 | SEC ↗ ×2 |
| 5 | Geode Capital Management ✦ (passief) | 7.39M | +1.1% | $2.91B | 0.2% | ▲ Add | 5 | SEC ↗ ×2 |
| 6 | Fidelity (FMR) ✦ | 7.15M | n/a | $2.83B | 0.2% | n/c | 1 | SEC ↗ ×7 |
| 7 | Wellington Management ✦ | 5.56M | -13.1% | $2.20B | 0.4% | ▼ Trim | 5 | SEC ↗ ×6 |
| 8 | Norges Bank ✦ (passief) | 4.76M | -6.3% | $1.88B | 0.2% | ▼ Trim | 5 | SEC ↗ |
| 9 | Fisher Asset Management ✦ | 3.45M | -5.6% | $1.37B | 0.5% | ▼ Trim | 5 | SEC ↗ |
| 10 | PRIMECAP Management ✦ | 504.76K | +16.1% | $199.70M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 11 | Two Sigma Investments ✦ | 480.54K | +111.1% | $190.12M | 0.4% | ▲ Add | 5 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 414.91K | -37.6% | $164.15M | 0.2% | ▼ Trim | 5 | SEC ↗ ×2 |
| 13 | Adage Capital Partners ✦ | 235.48K | +75.3% | $93.16M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 123.39K | +8.4% | $48.59M | 0.0% | ▲ Add | 5 | SEC ↗ ×5 |
| 15 | GAMCO Investors ✦ | 22.18K | +2.1% | $8.77M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 16 | Gotham Asset Management ✦ | 12.39K | +35.2% | $4.90M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 17 | Bridgewater Associates ✦ | 11.87K | -23.4% | $4.69M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 18 | Marshall Wace ✦ | 5.70K | -75.1% | $2.26M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 19 | Millennium Management ✦ | 4.37K | -84.4% | $1.73M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 20 | Harris Associates (Oakmark) ✦ | 571 | Nieuw | $225,905 | 0.0% | New | 1 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Harris Associates (Oakmark) | $225,905 | 0.0% |
Verlaten
| Arrowstreet Capital | $8.74M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 2,274 houders, 283.44M aandelen, $87.41B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Director · 18 aand @ 225.19 · $4,054
Director · 3 aand @ 185.65 · $557
Director · 36 aand @ 193.21 · $6,956
Director · 11 aand @ 221.03 · $2,431
Director · 63 aand @ 202.21 · $12,739
Open-market verkopen (S)
Officer · 441 aand · $144,915
Director · 11.26K aand · $3.81M
Director · 40 aand · $13,272
Director · 440 aand · $146,598
Director · 200 aand · $66,786
Director · 80 aand · $26,804
Director · 320 aand · $107,774
Director · 2.31K aand · $780,062
Director · 10.81K aand · $3.67M
Director · 16.61K aand · $5.66M
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie